中国P站

Gut microbiota; Mucosal immunity; Vaccines; Secretory IgA; Probiotics; Prebiotics; Fecal Microbiota Transplantation; Dietary fibers; Bacteriophages; Maternal microbiota

Introduction

The gut microbiota plays a pivotal role in shaping mucosal immune responses to vaccines, particularly in the production of secretory IgA (sIgA) [1] Specific bacterial taxa and microbial metabolites can either enhance or suppress vaccine efficacy, making the gut microbiota a key target for modulating vaccine responses [1] Research indicates that the composition of the gut microbiota significantly impacts the development of sIgA responses after vaccination [2] Certain bacterial species can act as adjuvants, promoting stronger and more durable antibody responses in the gut mucosa [2] Strategies for modulating the gut microbiota to improve mucosal vaccine efficacy include prebiotics, probiotics, and Fecal Microbiota Transplantation (FMT) to enhance sIgA responses [3] The composition of early-life gut microbiota has a significant impact on the development of mucosal immunity and responses to oral vaccines [4] A diverse and balanced microbiota is crucial for optimal vaccine-induced sIgA production [4] Specific probiotic strains can enhance sIgA responses to mucosal vaccines by stimulating IgA-producing B cells in the Gut-Associated Lymphoid Tissue (GALT) [5] Short-Chain Fatty Acids (SCFAs), produced by gut bacteria, modulate mucosal immune responses and sIgA production; butyrate, for example, can promote B cell differentiation and antibody secretion [6] Specific dietary fibers can shape the gut microbiota and enhance sIgA responses to oral vaccines by promoting the growth of beneficial bacteria that stimulate IgA production [7] Bacteriophages can modulate the gut microbiota and improve mucosal vaccine responses by selectively targeting and eliminating specific bacteria, leading to enhanced sIgA production [8] Advances in understanding the complex interplay between the gut microbiota, mucosal immunity, and vaccine responses highlight the potential for personalized vaccine strategies based on individual microbiota profiles [9] Maternal microbiota can shape the infant's gut microbiota and influence vaccine efficacy, thus impacting the development of mucosal immunity in offspring and their responses to early-life vaccines [10]

Description

The gut microbiota profoundly influences mucosal immune responses to vaccines, particularly the production of Secretory Immunoglobulin A (sIgA) [1]. This influence stems from specific bacterial taxa and microbial metabolites that can either boost or dampen vaccine efficacy. Understanding this interplay is critical for developing more effective vaccination strategies. Key research has focused on how the gut's microbial composition directly impacts the development of sIgA responses post-vaccination [2]. Specific bacterial species can act as natural adjuvants, strengthening and prolonging antibody responses in the gut mucosa.

Several strategies aim to manipulate the gut microbiota to enhance mucosal vaccine efficacy. These include the use of prebiotics, probiotics, and Fecal Microbiota Transplantation (FMT) to bolster sIgA responses [3]. The early-life gut microbiota composition plays a crucial role in developing mucosal immunity and responses to oral vaccines [4]. A diverse and balanced microbiota is essential for optimizing vaccine-induced sIgA production, highlighting the importance of early microbial colonization.

Probiotic strains have been shown to enhance sIgA responses to mucosal vaccines [5]. These strains effectively stimulate IgA-producing B cells within the Gut-Associated Lymphoid Tissue (GALT). Additionally, Short-Chain Fatty Acids (SCFAs), produced by gut bacteria, significantly modulate mucosal immune responses and sIgA production [6]. For instance, butyrate promotes B cell differentiation and antibody secretion, underscoring the role of bacterial metabolites in immune modulation.

Dietary fibers also play a role in shaping the gut microbiota and improving sIgA responses to oral vaccines [7]. Certain fibers encourage the growth of beneficial bacteria that stimulate IgA production. Furthermore, bacteriophages can be used to modulate the gut microbiota and enhance mucosal vaccine responses [8]. These phages selectively target and eliminate specific bacteria, which can lead to increased sIgA production. Maternal microbiota also impacts the development of mucosal immunity in offspring and their responses to early-life vaccines [10]. A mother's microbiota can shape the infant's gut composition, thereby affecting vaccine efficacy. Finally, advances in understanding the intricate relationship between the gut microbiota, mucosal immunity, and vaccine responses suggest the possibility of personalized vaccine strategies tailored to individual microbiota profiles [9].

Conclusion

The gut microbiota significantly affects mucosal immune responses to vaccines, especially Secretory Immunoglobulin A (sIgA) production. Specific bacteria and their metabolites can either enhance or suppress vaccine effectiveness. Research shows that the composition of the gut microbiota is crucial for developing sIgA responses after vaccination; certain bacteria act as adjuvants, leading to stronger and more durable antibody responses in the gut mucosa. Strategies to modulate the gut microbiota to improve vaccine efficacy include using prebiotics, probiotics, and Fecal Microbiota Transplantation (FMT) to boost sIgA responses. The early-life gut microbiota composition is vital for mucosal immunity and responses to oral vaccines, with a diverse and balanced microbiota being key for optimal vaccine-induced sIgA production. Probiotic strains can enhance sIgA responses by stimulating IgA-producing B cells in the Gut-Associated Lymphoid Tissue (GALT). Short-Chain Fatty Acids (SCFAs), like butyrate, produced by gut bacteria, modulate mucosal immune responses and sIgA production, promoting B cell differentiation and antibody secretion. Dietary fibers shape the gut microbiota and improve sIgA responses by promoting beneficial bacteria that stimulate IgA production. Bacteriophages can also modulate the gut microbiota to enhance mucosal vaccine responses by selectively targeting and eliminating specific bacteria, leading to increased sIgA production. Maternal microbiota influences the development of mucosal immunity in offspring and their responses to early-life vaccines, shaping the infant's gut microbiota and affecting vaccine efficacy. The latest research highlights the potential for personalized vaccine strategies based on individual microbiota profiles.

References

1. Catherine LO, Neil G, Joshua P (2023) .Vaccines 11:992.

   , ,

2. Lin Y, Jie L, Xin Z (2023) .Frontiers in Immunology 14:1153591.

   , ,

3. S R, A V, C G (2021) .Mucosal Immunology 14:877-892.

   , ,

4. Hiroki F, Naomi MT, Hiroshi O (2020) .Mucosal Immunology 13:809-817.

   , ,

5. Ihab HI, Catherine O, Paula S (2021) .Gut Microbes 13:1-17.

   , ,

6. Kevin PS, Simone WG, Paul OS (2020) .Nature Microbiology 5:1379-1390.

   , ,

7. Liesbeth WvdE, Willem MdV, Hauke S (2019) .Frontiers in Microbiology 10:2195.

   , ,

8. Szu-Ting H, Tomonori T, Koen V (2019) .Immunology and Cell Biology 97:122-135.

   , ,

9. R W, C R, W P (2021) .Immunology and Cell Biology 99:360-379.

   , ,

10. Harinder K, Takashi K, Takeshi I (2019) .Mucosal Immunology 12:3-14.

    , ,